Acadia Fumes Over FDA Rejection of its Psychosis Drug Nuplazid
After getting approval for its Parkinson’s psychosis drug, Nuplazid, in 2016, Acadia Pharmaceuticals had been trying to stoke further growth by getting its drug approved for dementia-related psychosis (DRP), a …
Read More